{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:02Z","timestamp":1794047462739,"version":"4.8.0"},"reference-count":30,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>TOURMALINE-MM1, the only blinded randomized study in patients with relapsed and\/or refractory multiple myeloma (RRMM; \u22651 prior therapy) in the last 10 years, investigated ixazomib + lenalidomide + dexamethasone (IRd) versus lenalidomide + dexamethasone (Rd). Final overall survival (OS) data were based on a median follow-up of 85 months. In RRMM trials where patients have had 1-3 relapses after initial treatment, a high proportion receive subsequent therapy. Application of salvage therapies in blinded trials and newer modes of therapy can increasingly complicate the interpretation of OS. This analysis explores the impact of subsequent therapies on OS outcomes in TOURMALINE-MM1. The inverse probability of censoring weights (IPCW) method, marginal structural model (MSM), and rank-preserving structural failure time model (RPSFTM) were utilized to adjust for confounding on OS, introduced by subsequent therapies. Analyses were conducted for the intent-totreat (ITT) population and \u22652 prior lines subgroup. Unadjusted hazard ratio (HR) for IRd versus Rd was 0.94 (95% confidence interval [CI]: 0.78-1.13) in the ITT population. After adjusting for the impact of subsequent therapies by the RPSFTM method, estimated HR for IRd versus Rd in the ITT population was 0.89 (95% CI: 0.74-1.07). Adjusting with IPCW and MSM methods also showed an improvement in HR, favoring IRd. IRd may be particularly beneficial in patients with \u22652 prior lines of therapy (IPCW and MSM HR=0.52, 95% CI: 0.30-0.88; RPSFTM HR=0.68, 95% CI: 0.51-0.91). These analyses highlight the growing challenge of demonstrating OS benefit in MM patients and the importance of assessing confounding introduced by subsequent therapies when interpreting OS.<\/jats:p>","DOI":"10.3324\/haematol.2023.283713","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:06:56Z","timestamp":1709176016000},"page":"2585-2593","source":"Crossref","is-referenced-by-count":1,"title":["Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone"],"prefix":"10.3324","volume":"109","author":[{"given":"Karthik","family":"Ramasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Cranmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dabora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Labotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"64622","doi-asserted-by":"crossref","unstructured":"Branagan A, Lei M, Lou U, Raje N. Current treatment strategies for multiple myeloma. JCO Oncol Pract. 2020; 16(1):5-14.","DOI":"10.1200\/JOP.19.00244"},{"key":"64623","doi-asserted-by":"crossref","unstructured":"Richardson PG, Kumar SK, Masszi T. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021; 39(22):2430-2442.","DOI":"10.1200\/JCO.21.00972"},{"key":"64624","doi-asserted-by":"crossref","unstructured":"Richardson PG, Jacobus SJ, Weller EA. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387(2):132-147.","DOI":"10.1056\/NEJMoa2204925"},{"key":"64625","doi-asserted-by":"crossref","unstructured":"Holstein SA, Suman VJ, McCarthy PL. Should overall survival remain an endpoint for multiple myeloma trials?. Curr Hematol Malig Rep. 2019; 14(1):31-38.","DOI":"10.1007\/s11899-019-0495-9"},{"key":"64626","doi-asserted-by":"crossref","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018; 70:199-208.","DOI":"10.1016\/j.ctrv.2018.09.001"},{"key":"64627","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar S, Plesner T. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380(22):2104-2115.","DOI":"10.1056\/NEJMoa1817249"},{"key":"64628","doi-asserted-by":"crossref","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S. Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments. Front Oncol. 2020; 10:624661.","DOI":"10.3389\/fonc.2020.624661"},{"key":"64629","doi-asserted-by":"crossref","unstructured":"Moreau P, Masszi T, Grzasko N. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 374(17):1621-1634.","DOI":"10.1056\/NEJMoa1516282"},{"key":"64630","unstructured":"US Food and Drug Administration (FDA). Ninlaro (ixazomib) capsules. 2023."},{"key":"64631","unstructured":"European Medicines Agency (EMA). Ninlaro (ixazomib). 2023."},{"key":"64632","doi-asserted-by":"crossref","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ. Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020; 34(7):1875-1884.","DOI":"10.1038\/s41375-020-0711-6"},{"key":"64633","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Chen C, Spencer A. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23(11):2147-2152.","DOI":"10.1038\/leu.2009.147"},{"key":"64634","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Lonial S, Betts KA. Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018; 124(20):4032-4043.","DOI":"10.1002\/cncr.31680"},{"key":"64635","doi-asserted-by":"crossref","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018; 36(8):728-734.","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"64636","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Lonial S, White D. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020; 10(9):1-10.","DOI":"10.1038\/s41408-020-00357-4"},{"key":"64637","doi-asserted-by":"crossref","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-152.","DOI":"10.1056\/NEJMoa1411321"},{"key":"64638","unstructured":"clinicaltrials.gov.. A phase 3 study comparing oral ixazomib plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with relapsed and\/or refractory multiple myeloma. 2023."},{"key":"64639","doi-asserted-by":"crossref","unstructured":"Blair HA. Daratumumab: a review in relapsed and\/or refractory multiple myeloma. Drugs. 2017; 77(18):2013-2024.","DOI":"10.1007\/s40265-017-0837-7"},{"key":"64640","doi-asserted-by":"crossref","unstructured":"Lonial S, Weiss BM, Usmani SZ. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387(10027):1551-1560.","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"64641","unstructured":"Moreau P, Kumar SK, San Miguel J. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021; 22(3):e105-e118."},{"key":"64642","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Oriol A, Nahi H. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375(14):1319-1331.","DOI":"10.1056\/NEJMoa1607751"},{"key":"64643","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Spencer A, Attal M. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357(21):2123-2132.","DOI":"10.1056\/NEJMoa070594"},{"key":"64644","doi-asserted-by":"crossref","unstructured":"Weber DM, Chen C, Niesvizky R. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-2142.","DOI":"10.1056\/NEJMoa070596"},{"key":"64645","doi-asserted-by":"crossref","unstructured":"Lonial S, Dimopoulos M, Palumbo A. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7):621-631.","DOI":"10.1056\/NEJMoa1505654"},{"key":"64646","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Palumbo A. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17(1):27-38.","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"64647","doi-asserted-by":"crossref","unstructured":"Attal M, Richardson PG, Rajkumar SV. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394(10214):2096-2107.","DOI":"10.1097\/01.HS9.0000561576.58696.ae"},{"key":"64648","doi-asserted-by":"crossref","unstructured":"San-Miguel JF, Hungria VT, Yoon S-S. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014; 15(11):1195-1206.","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"64649","doi-asserted-by":"crossref","unstructured":"Latimer NR, Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching [Internet]. 2014.","DOI":"10.1016\/j.jval.2013.08.013"},{"key":"64650","unstructured":"National Institute for Health and Care Excellence (NICE). Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. Technology appraisal guidance [TA870]. 2023."},{"key":"64651","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283713\/76723","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283713\/77350","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11479\/76723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:53Z","timestamp":1794045953000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283713","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}